| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a57036e4339d4d44cbb4ccce6c175cb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate |
2019-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_543130b62858290a813c851fc3330d06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ea0e834b7c47d7a27eece4d6689f06d |
| publicationDate |
2020-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020085467-A1 |
| titleOfInvention |
Pharmaceutical composition for treating aplastic anemia |
| abstract |
The present invention pertains to a pharmaceutical composition for treating aplastic anemia, comprising romiplostim as an active ingredient. This pharmaceutical composition is characterized by: being administered subcutaneously once a week; and in that for the first four weeks after the start of administration, the amount administered is 10 μg/kg/week in terms of romiplostim, and from the fifth week, the amount is increased beyond 10 μg/kg/week, up to 20 μg/kg/week in terms of romiplostim. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023149443-A1 |
| priorityDate |
2018-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |